There is a business model hidden inside the body of a patient.

It begins with a diagnosis. It moves through fear, hope, treatment, insurance, billing, patents, pricing and the quiet desperation of families trying to buy more time. In that world, medicine is not only science. It is also commerce.

This week, the International Consortium of Investigative Journalists reported on new research suggesting that lower or less frequent doses of some high-cost cancer drugs could save global health systems more than $30 billion a year. The research focused heavily on Keytruda, one of the world’s bestselling cancer medicines.

The question is not whether cancer drugs matter. They do.

The question is whether patients are sometimes receiving more drug than they need while health systems pay more than they should, companies profit more than they must and many patients around the world are priced out completely.

That is not only a healthcare issue.

It is a business issue.

When the Dose Becomes the Price

The ICIJ report explains that Keytruda was originally approved with weight-based dosing, but Merck later moved to fixed dosing. Fixed dosing can simplify treatment. But it can also mean that smaller patients receive more medicine than may be necessary.

The new research suggests that for some cancer drugs, lower doses or longer intervals may work just as well while dramatically reducing cost.

If true across wider clinical settings, the implications are enormous.

Lower doses could mean more patients treated with the same supply. It could mean fewer clinic visits. It could mean lower toxicity. It could mean less financial pressure on public health systems. It could mean that life-extending drugs become available not only to the wealthy, the insured or the lucky, but to more people across the world.

This is where business ethics enters the room.

A drug company has the right to recover research costs and earn profit. But when a lifesaving medicine becomes a hundred-billion-dollar business, society has the right to ask whether the structure rewards access or exclusion.

The Global Access Problem

Cancer is not limited to rich countries.

But expensive cancer treatment often is.

When a one-year course of treatment costs more than many families, hospitals or governments can afford, the result is a silent rationing system. Some patients receive modern medicine. Others receive delay, debt or nothing.

The cruel part is that this scarcity may not always be scientifically necessary. If lower dosing can preserve effectiveness for some patients, then the current model may be wasting money, wasting medicine and wasting lives.

The business world often speaks of efficiency.

There may be no greater inefficiency than pricing lifesaving treatment beyond the reach of the people it could save.

Solutions That Put Patients First

The first solution is independent dose-optimization trials.

Governments, universities, nonprofit hospitals and philanthropies should fund studies that test lower or less frequent dosing for expensive drugs. Companies should not be the only ones deciding which dose becomes standard.

The second solution is value-based pricing.

If a lower dose produces the same outcome, public programs and insurers should not be locked into paying for a higher-cost regimen without review. Pricing should reflect patient benefit, not only corporate strategy.

The third solution is international pooled purchasing.

Countries can join together to negotiate cancer-drug prices, especially for medicines with large global demand. Smaller countries should not have to bargain alone against pharmaceutical giants.

The fourth solution is patent transparency.

Public databases should clearly show when drug patents expire, which secondary patents extend monopolies and how companies use legal strategies to delay competition.

The fifth solution is access-first licensing.

When public funding or public research helped develop a drug, access conditions should be built into the deal. If taxpayers help make medicine possible, the public should not be priced out of it.

The sixth solution is clinical guidelines that follow evidence.

Medical societies should rapidly review dose-optimization findings and update standards when evidence supports safe, effective lower dosing.

Profit Cannot Be the Only Prescription

The future of medicine cannot be built only around what the market will bear.

A patient with cancer is not a market opportunity first. A patient is a human being trying to live.

If lower dosing can safely treat more people, then the moral path is clear: test it, verify it, regulate it and use it.

The great promise of modern medicine is not simply that science can create miracles.

The promise is that those miracles can reach the people who need them.

A world that can develop lifesaving drugs but cannot deliver them fairly has not solved the problem.

It has only learned how to sell hope at a price many people cannot pay.